Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $75

Benzinga · 3d ago
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $75.